Price T Rowe Associates Inc. MD Invests $88,000 in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,009 shares of the company’s stock, valued at approximately $88,000.

Other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets increased its position in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences during the fourth quarter worth $242,000. Inspire Investing LLC increased its position in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after acquiring an additional 10,039 shares during the period. Griffin Asset Management Inc. increased its position in shares of Pulse Biosciences by 15.7% in the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after acquiring an additional 40,700 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the period. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Price Performance

NASDAQ PLSE opened at $19.01 on Monday. The stock’s fifty day moving average price is $14.39 and its 200 day moving average price is $10.94. Pulse Biosciences, Inc. has a 1 year low of $3.78 and a 1 year high of $20.44. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -23.47 and a beta of 1.75.

Analyst Ratings Changes

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Tuesday, August 6th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.